Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Director | May 12, 2026 | May 14, 2026 |
| Terns Pharmaceuticals, Inc.TERN · Entity 49595 | Director | June 11, 2025 | June 12, 2025 |
| Turning Point Therapeutics, Inc.TPTX · Entity 124461 | Director | April 22, 2019 | April 24, 2019 |
| Zenas BioPharma, Inc.ZBIO · Entity 275 | Director | June 15, 2026 | June 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,012 |
Reported balance
After 2026-05-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-12 · Sale · Disposed 2,970 · Balance 52,012 F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.
Terns Pharmaceuticals, Inc.
Report date June 11, 2025 · Filed June 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.10 · Expires 2035-06-10 | Direct | 45,000 |
Reported balance
After 2025-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-11 · Grant · Acquired 45,000 · Balance 45,000 F1: The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant.
Turning Point Therapeutics, Inc.
Report date April 22, 2019 · Filed April 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LAV Prime Limited | 1,727,550 |
Last balance in matching sequence
After 2019-04-22 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2019-04-22 · Conversion · Acquired 1,120,730 · Balance 1,120,730 F1: Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date. F2: The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited. Row 2 · 2019-04-22 · Conversion · Acquired 546,820 · Balance 1,667,550 F1: Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date. F2: The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited. Row 3 · 2019-04-22 · Purchase · Acquired 60,000 · Balance 1,727,550 F3: The shares were purchased at the Issuer's initial public offering. F2: The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.06 · Expires 2029-04-21 | Direct | 15,000 |
Reported balance
After 2019-04-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-04-22 · Grant · Acquired 15,000 · Balance 15,000 F4: The option will become fully vested on the date of the Issuer's 2020 annual meeting of stockholders. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy LAV Prime Limited | 0 |
Reported balance
After 2019-04-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-04-22 · Conversion · Disposed 4,314,809 · Balance 0 F1: Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date. F2: The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectBy LAV Prime Limited | 0 |
Reported balance
After 2019-04-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-04-22 · Conversion · Disposed 2,105,259 · Balance 0 F1: Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date. F2: The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date.
F2: The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited.
F3: The shares were purchased at the Issuer's initial public offering.
F4: The option will become fully vested on the date of the Issuer's 2020 annual meeting of stockholders.
Zenas BioPharma, Inc.
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.71 · Expires 2036-06-15 | Direct | 18,500 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 18,500 · Balance 18,500 F1: The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AVEDRO INC
Report date November 21, 2019 · Filed November 25, 2019
Section 16 reporting ended · disclosed 2019-11-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.73 · Expires 2029-01-08 | Direct | 0 |
Reported balance
After 2019-11-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-11-21 · Disposition to issuer · Disposed 8,314 · Balance 0 F1: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-11-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-21 · Disposition to issuer · Disposed 3,005 · Balance 0 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. |
Filing footnotes · ownership attribution and instrument terms
F1: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F3: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 17, 2026 22:03 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $18.71 | $0.00 |
DisclosureSEC source: 0001104659-26-075257 · tm2618042-9_4seq1.xml · derivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2036-06-15 F1 · derivative.exercise_date: The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service. Read SEC document |
| May 12, 2026 Filed May 14, 2026 23:05 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,970 | $76.88 | $228,333.60 |
DisclosureSEC source: 0001767584-26-000002 · wk-form4_1778799941.xml · nonDerivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,012 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| March 31, 2026 Filed Mar 31, 2026 21:00 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 75,000 | $20.00 | $1,500,000.00 |
DisclosureSEC source: 0001104659-26-037865 · tm2610681-1_4seq1.xml · nonDerivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 422,968 F1 · kind: Acquired in an underwritten public offering, pursuant to which Zenas BioPharma, Inc. sold shares of common stock at a purchase price of $20.00 per share. F2 · ownership.direct: The reported securities are owned directly by NEXTBio Master Fund LP or NEXTBio Evergreen LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP (with respect to such securities directly owned by NEXTBio Master Fund LP), (ii) NEXTBio Capital Evergreen GP LLC, the managing member of NEXTBio Evergreen LLC (with respect to such securities directly owned by NEXTBio Evergreen LLC), (iii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP and NEXTBio Evergreen LLC, and (iv) Hongbo Lu, a managing member of NEXTBio Capital LLC and NEXTBio Capital Evergreen GP LLC. F3 · ownership.direct: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F2 · ownership.nature: The reported securities are owned directly by NEXTBio Master Fund LP or NEXTBio Evergreen LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP (with respect to such securities directly owned by NEXTBio Master Fund LP), (ii) NEXTBio Capital Evergreen GP LLC, the managing member of NEXTBio Evergreen LLC (with respect to such securities directly owned by NEXTBio Evergreen LLC), (iii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP and NEXTBio Evergreen LLC, and (iv) Hongbo Lu, a managing member of NEXTBio Capital LLC and NEXTBio Capital Evergreen GP LLC. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 21:02 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 3,768 | $18.63 | $70,197.84 |
DisclosureSEC source: 0001104659-26-039240 · tm2611015-1_4seq1.xml · nonDerivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 426,736 F1 · ownership.nature: The reported securities are owned directly by NEXTBio Master Fund LP or NEXTBio Evergreen LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP (with respect to such securities directly owned by NEXTBio Master Fund LP), (ii) NEXTBio Capital Evergreen GP LLC, the managing member of NEXTBio Evergreen LLC (with respect to such securities directly owned by NEXTBio Evergreen LLC), (iii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP and NEXTBio Evergreen LLC, and (iv) Hongbo Lu, a managing member of NEXTBio Capital LLC and NEXTBio Capital Evergreen GP LLC. F2 · ownership.nature: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 22:35 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 25,985 | $22.50 | $584,662.50 |
DisclosureSEC source: 0001104659-26-015387 · tm266411-2_4seq1.xml · nonDerivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 347,968 F1 · ownership.direct: The reported securities are owned directly by NEXTBio Master Fund LP or NEXTBio Evergreen LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP (with respect to such securities directly owned by NEXTBio Master Fund LP), (ii) NEXTBio Capital Evergreen GP LLC, the managing member of NEXTBio Evergreen LLC (with respect to such securities directly owned by NEXTBio Evergreen LLC), (iii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP and NEXTBio EverGreen LLC, and (iv) Hongbo Lu, a managing member of NEXTBio Capital LLC and NEXTBio Capital Evergreen GP LLC. F2 · ownership.direct: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The reported securities are owned directly by NEXTBio Master Fund LP or NEXTBio Evergreen LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP (with respect to such securities directly owned by NEXTBio Master Fund LP), (ii) NEXTBio Capital Evergreen GP LLC, the managing member of NEXTBio Evergreen LLC (with respect to such securities directly owned by NEXTBio Evergreen LLC), (iii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP and NEXTBio EverGreen LLC, and (iv) Hongbo Lu, a managing member of NEXTBio Capital LLC and NEXTBio Capital Evergreen GP LLC. F2 · ownership.nature: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 23:40 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 7,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001767584-25-000004 · wk-form4_1766101211.xml · nonDerivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,982 F1 · shares: Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 19:37 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 263,160 | $19.00 | $5,000,040.00 |
DisclosureSEC source: 0000919574-25-006031 · ownership.xml · nonDerivative · entry 2 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 321,983 F2 · ownership.direct: The reported securities are owned directly by NEXTBio Master Fund LP or NextBio Evergreen LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP (with respect to such securities directly owned by NEXTBio Master Fund LP), (ii) NEXTBio Capital Evergreen GP LLC, the managing member of NEXTBio Evergreen LLC (with respect to such securities directly owned by NextBio Evergreen LLC), (iii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP and NextBio Evergreen LLC, and (iv) Hongbo Lu, a managing member of NEXTBio Capital LLC and NEXTBio Capital Evergreen GP LLC. F3 · ownership.direct: (Continued from footnote 2) The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F2 · ownership.nature: The reported securities are owned directly by NEXTBio Master Fund LP or NextBio Evergreen LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP (with respect to such securities directly owned by NEXTBio Master Fund LP), (ii) NEXTBio Capital Evergreen GP LLC, the managing member of NEXTBio Evergreen LLC (with respect to such securities directly owned by NextBio Evergreen LLC), (iii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP and NextBio Evergreen LLC, and (iv) Hongbo Lu, a managing member of NEXTBio Capital LLC and NEXTBio Capital Evergreen GP LLC. F3 · ownership.nature: (Continued from footnote 2) The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 21:44 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001562180-25-004759 · primarydocument.xml · derivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:31 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $11.94 | $0.00 |
DisclosureSEC source: 0001104659-25-058918 · tm2517684-2_4seq1.xml · derivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: The option vests as to 100% of the underlying shares of common stock on June 10, 2026, the first anniversary of the vesting commencement date, subject to continued service. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 00:37 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | GrantStock Option (Right to Buy) · Derivative | 10,657 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001562180-25-000858 · primarydocument.xml · derivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,657 Underlying: Common Stock · 10,657 shares Expires 2035-01-31 F1 · shares: This option was issued pursuant to the Issuer's Non-Employee Director Compensation Policy, under which the Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $40,000 for 2025. F2 · derivative.exercise_date: The option will vest as to 1/12th of the total shares subject thereto on each monthly anniversary measured from January 1, 2025, such that 100% of the shares subject to the option will be fully vested on January 1, 2026. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 23:04 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 16,733 | $22.99 | $384,691.67 |
DisclosureSEC source: 0001628280-24-052268 · wk-form4_1734735870.xml · nonDerivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,163 F1 · shares: Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary date. Read SEC document |
| September 25, 2024 Filed Nov 16, 2024 01:34 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 5,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-048162 · wk-form5_1731720845.xml · nonDerivative · entry 6 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,430 F2 · ownership.direct: On September 25, 2024, the Reporting Person transferred 5,650 shares of the Issuer's common stock from a jointly-held retirement account to her spouse's individual retirement account for no consideration. Read SEC document |
| September 13, 2024 Filed Sep 17, 2024 23:52 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 58,823 | $17.00 | $999,991.00 |
DisclosureSEC source: 0000919574-24-005530 · ownership.xml · nonDerivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 58,823 F1 · ownership.nature: The reported securities are owned directly by NEXTBio Master Fund LP and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP, (ii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP, and (iii) Hongbo Lu, a managing member of NEXTBio Capital LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 13, 2024 Filed Oct 9, 2025 19:37 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 58,823 | $17.00 | $999,991.00 |
DisclosureSEC source: 0000919574-25-006031 · ownership.xml · nonDerivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 58,823 F1 · ownership.direct: The reported securities are owned directly by NEXTBio Master Fund LP and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP, (ii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP, and (iii) Hongbo Lu, a managing member of NEXTBio Capital LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The reported securities are owned directly by NEXTBio Master Fund LP and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP, (ii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP, and (iii) Hongbo Lu, a managing member of NEXTBio Capital LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 12, 2024 Filed Sep 17, 2024 01:01 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantStock Option (Right to Buy) · Derivative | 37,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-24-100337 · tm2424157-10_4seq1.xml · derivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2034-09-11 F1 · derivative.exercise_date: The option vests in equal annual installments over three years beginning on September 12, 2025, the first anniversary of the vesting commencement date, subject to continued service. Read SEC document |
| September 12, 2024 Filed Sep 17, 2024 23:48 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | PurchaseCommon Stock | 285,714 | $10.50 | $2,999,997.00 |
DisclosureSEC source: 0000919574-24-005529 · ownership.xml · nonDerivative · entry 2 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 476,190 F2 · ownership.nature: The reported securities are owned directly by NEXTBio Opportunity Adapt LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital Opportunity Adapt GP, LLC, the managing member of NEXTBio Opportunity Adapt LLC, and (ii) Hongbo Lu, a managing member of NEXTBio Capital Opportunity Adapt GP, LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 12, 2024 Filed Sep 17, 2024 23:48 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | PurchaseCommon Stock | 190,476 | $10.50 | $1,999,998.00 |
DisclosureSEC source: 0000919574-24-005529 · ownership.xml · nonDerivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 190,476 F1 · ownership.nature: The reported securities are owned directly by NEXTBio Master Fund LP and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP, (ii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP, and (iii) Hongbo Lu, a managing member of NEXTBio Capital LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 22:36 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | GrantStock Option (Right to Buy) · Derivative | 4,676 | $0.00 Strike: $6.85 | $0.00 |
DisclosureSEC source: 0001562180-24-005548 · primarydocument.xml · derivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,676 Underlying: Common Stock · 4,676 shares Expires 2034-06-30 F1 · shares: This option was issued pursuant to the Issuer's Non-Employee Director Compensation Policy, under which the Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $20,000 for the third and fourth quarters of 2024. F2 · derivative.exercise_date: The option will vest as to 1/6th of the total shares subject thereto on each monthly anniversary of the date of grant, such that 100% of the shares subject to the option will be fully vested on January 1, 2025. Read SEC document |
| June 10, 2024 Filed Jun 14, 2024 22:04 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $6.99 | $0.00 |
DisclosureSEC source: 0001562180-24-005104 · primarydocument.xml · derivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2034-06-09 F1 · derivative.exercise_date: The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant. Read SEC document |
| April 18, 2024 Filed Nov 16, 2024 01:34 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 500 | $22.00 | $11,000.00 |
DisclosureSEC source: 0001628280-24-048162 · wk-form5_1731720845.xml · nonDerivative · entry 5 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,080 F1 · balance_after: Includes previously reported restricted stock units, which are subject to certain vesting conditions. Read SEC document |
| April 10, 2024 Filed Nov 16, 2024 01:34 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 500 | $25.00 | $12,500.00 |
DisclosureSEC source: 0001628280-24-048162 · wk-form5_1731720845.xml · nonDerivative · entry 4 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,580 F1 · balance_after: Includes previously reported restricted stock units, which are subject to certain vesting conditions. Read SEC document |
| April 02, 2024 Filed Nov 16, 2024 01:34 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 150 | $27.34 | $4,101.00 |
DisclosureSEC source: 0001628280-24-048162 · wk-form5_1731720845.xml · nonDerivative · entry 3 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,080 F1 · balance_after: Includes previously reported restricted stock units, which are subject to certain vesting conditions. Read SEC document |
| March 26, 2024 Filed Nov 16, 2024 01:34 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 850 | $27.50 | $23,375.00 |
DisclosureSEC source: 0001628280-24-048162 · wk-form5_1731720845.xml · nonDerivative · entry 2 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,930 F1 · balance_after: Includes previously reported restricted stock units, which are subject to certain vesting conditions. Read SEC document |
| March 22, 2024 Filed Nov 16, 2024 01:34 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 400 | $28.00 | $11,200.00 |
DisclosureSEC source: 0001628280-24-048162 · wk-form5_1731720845.xml · nonDerivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,080 F1 · balance_after: Includes previously reported restricted stock units, which are subject to certain vesting conditions. Read SEC document |
| March 20, 2024 Filed Mar 20, 2024 23:06 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 1,000 | $27.50 | $27,500.00 |
DisclosureSEC source: 0001628280-24-012327 · wk-form4_1710976009.xml · nonDerivative · entry 3 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,680 Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 23:06 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 1,000 | $28.00 | $28,000.00 |
DisclosureSEC source: 0001628280-24-012327 · wk-form4_1710976009.xml · nonDerivative · entry 2 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,680 Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 23:06 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 1,000 | $27.49 | $27,490.00 |
DisclosureSEC source: 0001628280-24-012327 · wk-form4_1710976009.xml · nonDerivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,680 F1 · price: The price reported on Column 4 is the weighted average price. These shares were purchase in multiple transactions at prices ranging from $ 27.48 to $ 27.50, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 23:01 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $12.05 | $0.00 |
DisclosureSEC source: 0001562180-23-005168 · primarydocument.xml · derivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2033-06-11 F1 · derivative.exercise_date: The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant. Read SEC document |
| December 23, 2022 Filed Dec 23, 2022 22:44 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | PurchaseCommon Stock | 758,620 | $7.25 | $5,499,995.00 |
DisclosureSEC source: 0001562180-22-008428 · primarydocument.xml · nonDerivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,340,212 F1 · ownership.nature: The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. As a managing member of Vivo Opportunity, LLC, Hongbo Lu shares voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. with four other managing members but disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 00:00 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | PurchaseCommon Stock | 600,000 | $3.60 | $2,160,000.00 |
DisclosureSEC source: 0001562180-22-006567 · primarydocument.xml · nonDerivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,581,592 F1 · ownership.nature: The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. As a managing member of Vivo Opportunity, LLC, Hongbo Lu shares voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. with four other managing members but disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 00:30 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | PurchasePre-funded Warrants (right to buy) · Derivative | 1,500,000 | $2.42 Strike: $0.00 | $3,629,850.00 |
DisclosureSEC source: 0001562180-22-006125 · primarydocument.xml · derivative · entry 4 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires not disclosed F4 · kind: Vivo Opportunity Fund Holdings, L.P. acquired 1,500,000 shares of Common Stock at $2.42 per share and 1,500,000 pre-funded warrants at $2.4199 per warrant in an underwritten offering. F5 · derivative.exercise_date: The pre-funded warrants have no expiration date and are exercisable immediately, subject to a 4.99% beneficial ownership limit. F5 · derivative.expiration_date: The pre-funded warrants have no expiration date and are exercisable immediately, subject to a 4.99% beneficial ownership limit. F2 · ownership.nature: The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. As a managing member of Vivo Opportunity, LLC, Hongbo Lu shares voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. with four other managing members but disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 00:30 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | PurchaseCommon Stock | 1,500,000 | $2.42 | $3,630,000.00 |
DisclosureSEC source: 0001562180-22-006125 · primarydocument.xml · nonDerivative · entry 3 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,981,592 F4 · kind: Vivo Opportunity Fund Holdings, L.P. acquired 1,500,000 shares of Common Stock at $2.42 per share and 1,500,000 pre-funded warrants at $2.4199 per warrant in an underwritten offering. F4 · price: Vivo Opportunity Fund Holdings, L.P. acquired 1,500,000 shares of Common Stock at $2.42 per share and 1,500,000 pre-funded warrants at $2.4199 per warrant in an underwritten offering. F2 · ownership.nature: The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. As a managing member of Vivo Opportunity, LLC, Hongbo Lu shares voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. with four other managing members but disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 00:30 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | PurchaseCommon Stock | 1,218 | $2.99 | $3,641.82 |
DisclosureSEC source: 0001562180-22-006125 · primarydocument.xml · nonDerivative · entry 2 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,481,592 F3 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $2.96 to $3.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4. F2 · ownership.nature: The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. As a managing member of Vivo Opportunity, LLC, Hongbo Lu shares voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. with four other managing members but disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein. Read SEC document |
| August 12, 2022 Filed Aug 17, 2022 00:30 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | PurchaseCommon Stock | 1,123,021 | $2.98 | $3,346,602.58 |
DisclosureSEC source: 0001562180-22-006125 · primarydocument.xml · nonDerivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,480,374 F1 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $2.83 to $3.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. As a managing member of Vivo Opportunity, LLC, Hongbo Lu shares voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. with four other managing members but disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 01:00 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001562180-22-005265 · primarydocument.xml · derivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:04 UTC | Terns Pharmaceuticals, Inc. TERN · Entity 49595 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $22.06 | $0.00 |
DisclosureSEC source: 0001567619-21-005069 · doc1.xml · derivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-23 F1 · derivative.exercise_date: 1/3rd of the shares subject to the option vest on the first anniversary measured from February 24, 2021 (the "Vesting Commencement Date"), and 1/36th of the total number of shares vest on each monthly anniversary thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 16:31 UTC | AVEDRO INC AVDR · Entity 153528 | Disposition to issuerRestricted Stock Units · Derivative | 3,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-057938 · doc4.xml · derivative · entry 2 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,005 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · price: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. F3 · derivative.exercise_date: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. F3 · derivative.expiration_date: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 16:31 UTC | AVEDRO INC AVDR · Entity 153528 | Disposition to issuerStock Option (right to buy) · Derivative | 8,314 | Not disclosed Strike: $12.73 | Not disclosed |
DisclosureSEC source: 0001209191-19-057938 · doc4.xml · derivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,314 shares Expires 2029-01-08 F1 · price: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. F1 · derivative.exercise_date: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 19:50 UTC | AVEDRO INC AVDR · Entity 153528 | GrantRestricted Stock Units · Derivative | 3,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037845 · doc4.xml · derivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,005 Underlying: Common Stock · 3,005 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest on June 1, 2020, subject to Reporting Person's continuous service through such date. F2 · derivative.expiration_date: The RSUs vest on June 1, 2020, subject to Reporting Person's continuous service through such date. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 18:11 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | ConversionSeries D Preferred Stock · Derivative | 2,105,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-025793 · doc4.xml · derivative · entry 6 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LAV Prime Limited Disclosed balance after: 0 Underlying: Common Stock · 546,820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date. F1 · derivative.exercise_date: Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date. F1 · derivative.expiration_date: Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date. F2 · ownership.nature: The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 18:11 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | ConversionSeries C Preferred Stock · Derivative | 4,314,809 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-025793 · doc4.xml · derivative · entry 5 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LAV Prime Limited Disclosed balance after: 0 Underlying: Common Stock · 1,120,730 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date. F1 · derivative.exercise_date: Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date. F1 · derivative.expiration_date: Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date. F2 · ownership.nature: The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 18:11 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $27.06 | $0.00 |
DisclosureSEC source: 0001209191-19-025793 · doc4.xml · derivative · entry 4 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-04-21 F4 · derivative.exercise_date: The option will become fully vested on the date of the Issuer's 2020 annual meeting of stockholders. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 18:11 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | PurchaseCommon Stock | 60,000 | $18.00 | $1,080,000.00 |
DisclosureSEC source: 0001209191-19-025793 · doc4.xml · nonDerivative · entry 3 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LAV Prime Limited Disclosed balance after: 1,727,550 F3 · kind: The shares were purchased at the Issuer's initial public offering. F2 · ownership.nature: The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 18:11 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | ConversionCommon Stock | 546,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-025793 · doc4.xml · nonDerivative · entry 2 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LAV Prime Limited Disclosed balance after: 1,667,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date. F1 · price: Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date. F2 · ownership.nature: The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 18:11 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | ConversionCommon Stock | 1,120,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-025793 · doc4.xml · nonDerivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LAV Prime Limited Disclosed balance after: 1,120,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date. F1 · price: Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date. F2 · ownership.nature: The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited. Read SEC document |
| February 19, 2019 Filed Feb 19, 2019 19:13 UTC | AVEDRO INC AVDR · Entity 153528 | GrantStock Option (right to buy) · Derivative | 8,314 | $0.00 Strike: $12.73 | $0.00 |
DisclosureSEC source: 0001209191-19-011334 · doc4.xml · derivative · entry 1 Lu Hongbo · CIK 0001767584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,314 Underlying: Common Stock · 8,314 shares Expires 2029-01-08 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (x) June 1, 2020 and (y) the first anniversary of the first annual meeting of the Issuer's stockholders following the Issuer's initial public offering, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.